2013 will be a very exciting year for ONXX. Nexavar, Kyprolis, Stivarga, PD-0332991 not to mention existing programs
Sentiment: Strong Buy
Yes expect 2013 to be great. STORM trial, breast cancer trial further along, GIST related approval (anytime now), and Nexavar regulatory submission for thyroid cancer type
ONXX as a well positioned commercial stage company might be a perfect fit for an acquisition.